1. Compute the proportion of subjects experiencing the primary outcome for both the aerosol and injection groups. 2. Can we safely use the large-sample confidence interval for comparing the proportion of children who developed an immune response to measles in the aerosol and injection groups?
An aerosolized vaccine for measles was developed in Mexico and has been used on more than 4 million children since 1980. Aerosolized vaccines have the advantages of being able to be administered by people without clinical training and do not cause injection-associated infections. Despite these advantages, data about efficacy of the aerosolized vaccines against measles compared to subcutaneous injection of the vaccine have been inconsistent. Because of this, a large randomized controlled study was conducted using children in India. The primary outcome was an immune response to measles measured 91 days after the treatments. Among the 785 children receiving the subcutaneous injection, 743 developed an immune response, while among the 775 children receiving the aerosolized vaccine, 662 developed an immune response.3
1. Compute the proportion of subjects experiencing the primary outcome for both the aerosol and injection groups.
2. Can we safely use the large-sample confidence interval for comparing the proportion of children who developed an immune response to measles in the aerosol and injection groups?
Trending now
This is a popular solution!
Step by step
Solved in 2 steps with 2 images
